Axsome Therapeutics vs Supernus Pharmaceuticals
Axsome Therapeutics and Supernus Pharmaceuticals are similar in size: $638m and $719m of revenue in their latest fiscal years. Axsome Therapeutics grew faster (65.5% against 8.6%). Supernus Pharmaceuticals kept more of each dollar of sales as profit: a net margin of -5.4% against -28.7%. Supernus Pharmaceuticals carries less debt relative to equity (0.0% against 212.6%).
| Latest fiscal year | Axsome TherapeuticsAXSM, 2025 | Supernus PharmaceuticalsSUPN, 2025 |
|---|---|---|
| Revenue | $638m | $719m |
| Revenue growth | 65.5% | 8.6% |
| Net income | −$183m | −$38.5m |
| Operating margin | -26.1% | -8.7% |
| Net margin | -28.7% | -5.4% |
| Return on equity | — | -3.7% |
| Free cash flow | −$93.9m | $46.0m |
| Cash | $323m | $128m |
| Total debt | $188m | $0 |
| Debt to equity | 212.6% | 0.0% |
| Dividend per share | — | — |
| Dividend yield | — | — |
| Share buybacks | — | — |
| Employees | — | 778 |
| Market value | $7.38bn | $1.65bn |
| Price vs our value range | — | Below our value range |
| Moat score | — | 69 (Moderate) |
| Insider trades, 12 months | 0 buys, 33 sales | 0 buys, 20 sales |